Live
- Sharad Pawar urges Shinde to call meeting to mull ways to end drought in Pune District
- Russian President Putin to visit North Korea, Vietnam
- Athletics: Neeraj Chopra to take part in Paavo Nurmi Games in Finland
- JD(U) MP Devesh Chandra Thakur Sparks Controversy With Remarks On Muslim And Yadav Communities
- Complete irrigation projects on time, Majhi tells officers
- Swara Bhasker critiques food blogger's vegetarian pride, sparks controversy
- Vietnamese banks no longer crowded with gold buyers after online registration opens
- Eating samosa, burger when stressed out can fuel anxiety: Study
- Giving ample water, Delhi facing crisis because of inefficient govt: Haryana CM
- Senior K'taka BJP leader dies of heart attack after protest against fuel price hike
Glenmark Pharmarolls outlow-cost drug for diabetes
Glenmark Pharmaceuticals, a drug major on Thursday launched a patent protected sodium glucose co-transporter (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.
Hyderabad: Glenmark Pharmaceuticals, a drug major on Thursday launched a patent protected sodium glucose co-transporter (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.
The drug is indicated in the treatment of type-2 diabetes mellitus in adults.
The drug was launched under brand names Remo and Remozen, at a price of Rs 12.50 per tablet.
The new diabetic drug, Remogliflozin, was discovered and developed by Japanese firm Kissei Pharmaceutical Co Ltd and later developed by GlaxoSmithKline plc and Glenmark collaborator BHV Pharma, a wholly owned subsidiary of North Carolina USA-based Avolynt, Inc.
The drug company expects 12 to 14 per cent growth in its India revenues during the current fiscal, Sujesh Vasudevan, President, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals said.
